A placebo-controlled, randomized, parallel-group, adaptive, phase 2 study has been set in June 2023 to evaluate the safety and efficacy of liposomal zinc, liposomal bovine lactoferrin, and standard of care compared to placebo and standard of care in non-hospitalized patients with COVID-19 for 10 days [248]. The gene discussed is LTF; the disease is COVID-19.